Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial
Table 3
Changes in clinical characteristics and laboratory indices in the control group from baseline to month 6.
Baseline
Month 6
Mean difference
value
Body weight (kg)
0.654
Body mass index (kg/m2)
0.619
Mean arterial blood pressure
0.856
Hemoglobin (g/dL)
0.012
Estimated GFR (mL/min/1.73 m2)
0.116
BUN (mg/dL)
0.004
Serum creatinine (mg/dL)
0.004
Fasting plasma glucose (mg/dL)
0.065
Hemoglobin A1C (%)
0.451
Serum potassium (mEq/L)
0.183
Serum magnesium (mg/dL)
0.128
Serum calcium (mg/dL)
0.729
Serum phosphate (mg/dL)
0.316
Serum albumin (g/dL)
0.239
Urine protein, 24 hours (g/day)
0.060
Coronary artery calcium score
0.395
CAVI
0.005
Serum myeloperoxidase (μg/L)
0.934
Serum osteopontin (ng/mL)
0.305
Serum bone alkaline phosphatase (μg/L)
0.947
Urine NGAL (ng/mg creatinine)
0.024
Urine Kim (ng/mg creatinine)
<0.001
Urine LFABP (μg/mg creatinine)
0.488
Data are presented as the . CAVI: cardio-ankle vascular index; LFABP: liver acid-binding protein; NGAL: neutrophil gelatinase-associated lipocalin; Kim-1: kidney injury molecule-1.
